0001488917 false 0001488917 2023-06-05 2023-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

     

 

FORM 8-K

 

     

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 5, 2023

 

     

ELECTROMED, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Minnesota 001-34839 41-1732920

(State or Other Jurisdiction of

Incorporation)

(Commission File Number)

(I.R.S. Employer Identification

Number)

 

500 Sixth Avenue NW

New Prague, MN 56071

(Address of Principal Executive Offices) (Zip Code)

 

(952) 758-9299

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

     

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.01 par value   ELMD   NYSE American LLC
(Title of each class)   (Trading Symbol)   (Name of each exchange on which registered)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 5, 2023, Electromed, Inc. (the "Company") announced the appointment of James L. Cunniff to serve as its next Chief Executive Officer and President, beginning July 1, 2023. The Company's board of directors (the "Board") has also approved an increase in its size to nine members and appointed Mr. Cunniff to serve as an additional director effective as of the same date. Mr. Cunniff will not serve on any committees.

Mr. Cunniff, age 58, most recently served as President and Chief Executive Officer of Provista Inc., from 2017 to May 2022. Previously, he served as President and Chief Executive Officer at Denver Solutions, LLC (d/b/a Leiters Health) from 2015 to 2017 and as Senior Vice President, Americas, at Acelity L.P. Inc., from 2012 to 2014. Mr. Cunniff holds a bachelor's degree in Advertising and Business from the University of Illinois Urbana-Champaign and has completed the Advanced Management Program at Harvard Business School.

On May 22, 2023, the Company entered into an employment agreement with Mr. Cunniff, to become effective as of July 1, 2023, pursuant to which he will receive an initial annual base salary of $500,000. He will be eligible to participate in the Company's annual officer bonus plan, beginning with the fiscal year ending June 30, 2024, with a target payout equal to 50% of annual base salary. He also will be eligible to participate in the Company's annual equity incentive grants and will receive an initial grants of (a) 175,000 performance-based restricted stock units and (b) options to purchase 175,000 shares of common stock, each in the form of inducement awards on terms substantially similar to the Company's 2017 Omnibus Incentive Plan and effective as soon as practicable on or after his first day of employment. The option is expected to vest with respect to 25% of the shares on the first anniversary of the date of grant and then quarterly over the remaining three years in twelve equal increments. The performance-based restricted stock units will be eligible to vest and settle into shares of common stock on a 1-for-1 basis with respect to one-half of the shares upon achieving a total shareholder return of 50% and the remaining shares upon a total shareholder return of 100%, in each case within four years of the date of grant. On the same date, the Company entered into a letter agreement with Mr. Cunniff pursuant to which he will be entitled to relocation assistance of up to $30,000. He will be eligible to participate in the other compensation and benefits programs generally available to Company employees.

If his employment is terminated by us for any reason other than for "cause" (as defined in his employment agreement) or is terminated by him for "good reason" (as defined in his employment agreement), and such termination occurs before a change in control (as defined in his employment agreement), then he will be eligible to (A) receive an amount equal to (i) one times his annualized base salary as of the termination date, payable in installments over 12 months, plus (ii) an amount equal to a prorated portion of his target annual bonus based on the Company's performance for the fiscal year in which the termination date occurs, payable in a lump sum, and (B) have us continue to pay the Company portion of COBRA premiums for up to 12 months.

If any such termination occurs within twelve months after a change of control, then he would instead be eligible to (A) receive an amount equal to (i) receive an amount equal to (i) one times his annualized base salary as of the termination date, plus (ii) an amount equal to 100% of his target annual bonus that was based on his individual performance for the fiscal year in which the termination date occurs, payable in a lump sum, (B) have us continue to pay the Company portion of COBRA premiums for up to 12 months.

All of the foregoing severance benefits remain contingent on Mr. Cunniff signing and not revoking a release of claims and his remaining in strict compliance with the terms of his employment agreement, any supplemental non-competition, non-solicitation, and confidentiality agreement with the Company, and any other written agreement between him and the Company.

The foregoing description of the material terms of the Employment Agreement and the letter agreement are qualified by the full text thereof, which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K, respectively, and incorporated by reference into this Item 5.02.

To facilitate a return to a Board size of eight members, current director Lee A. Jones will not stand for election and is expected to serve the remainder of her term as a member of the Board, which is scheduled to expire at the Company's next annual meeting of shareholders expected to be held in November 2023.

 

 

Item 7.01Regulation FD Disclosure.

 

The full text of the Company's press release announcing Mr. Cunniff's appointment is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item 7.01.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit Number   Description
     
10.1   Employment Agreement with James Cunniff dated May 22, 2023
     
10.2   Letter Agreement with James Cunniff dated May 22, 2023
     
99.1   Press Release dated June 5, 2023
     
104   Cover Page Interactive Data File (embedded in the cover page and formatted in inline XBRL)

The information contained in Item 7.01, Exhibit 99.1 and Exhibit 99.2 of this Current Report on Form 8-K shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Cautionary Statements

Certain statements in this Current Report on Form 8-K constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “assume,” “believe,” “expect,” “may,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, the duration, extent and severity of the COVID-19 pandemic, including its effects on its business, supply chain, operations and employees as well as its impact on its customers and distribution channels and on economies and markets more generally; the competitive nature of the Company’s market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; the Company’s ability to develop new sales channels for its products such as the homecare distributor channel; the Company’s need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; the Company’s ability to renew its line of credit or obtain additional credit as necessary; the Company’s ability to protect and expand its intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors the Company may describe from time to time in its reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update them in light of new information or future events.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   ELECTROMED, INC.   
        
Date:  June 5, 2023 By: /s/ Bradley M. Nagel   
   Name: Bradley M. Nagel   
   Title: Chief Financial Officer   

 

 

Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (“Agreement”) is made effective as of July 1, 2023 (the “Effective Date”) by and between Electromed, Inc., a Minnesota corporation (the “Corporation”) and James Cunniff, an individual (“Employee”) (collectively “Parties” or individually “Party”).

 

RECITALS

 

WHEREAS, the Corporation desires to employ Employee, and Employee desires to be employed by the Corporation;

 

WHEREAS, Employee acknowledges that Employee will be employed in a position of trust and confidence and will have access to proprietary, confidential and/or trade secret information of the Corporation; and

 

WHEREAS, the Corporation and Employee desire to enter into this Agreement, which will govern the terms of Employee’s employment with the Corporation.

 

NOW, THEREFORE, in consideration of the employment of Employee by the Corporation, the severance-related protections Employee is receiving from the Corporation pursuant to the terms of this Agreement, the salary, wages or other compensation and benefits that will be provided by the Corporation to Employee, Employee’s access to the Corporation’s proprietary, confidential and/or trade secret information, and for additional mutual covenants and conditions, the receipt and sufficiency of which are hereby acknowledged, the Corporation and Employee, intending legally to be bound, hereby agree as follows:

 

AGREEMENT

 

In consideration of the above recitals and the mutual promises set forth in this Agreement, the Parties agree as follows:

 

1.                Nature and Capacity of Employment.

 

1.1             Title and Duties. The Corporation will employ Employee as its President and Chief Executive Officer pursuant to the terms and conditions set forth in this Agreement. Employee will perform such duties and responsibilities for the Corporation as the Corporation’s Board of Directors (the “Board”) may assign to Employee from time to time consistent with Employee’s position. Employee shall serve the Corporation faithfully and to the best of Employee’s ability and shall at all times act in accordance with the law. Employee shall devote Employee’s full working time, attention and efforts to performing Employee’s duties and responsibilities under this Agreement and advancing the Corporation’s business interests. Employee shall follow applicable policies and procedures adopted by the Corporation from time to time, including without limitation the Corporation’s Confidentiality Policy and other Corporation policies, including those relating to business ethics, conflict of interest and non-discrimination. Employee shall not, without the prior written consent of the Board, accept other employment or engage in other business activities during Employee’s employment with the Corporation that may prevent Employee from fulfilling the duties or responsibilities as set forth in or contemplated by this Agreement. Notwithstanding the foregoing, Employee shall be permitted to continue Employee’s current board position on the board of AA Medical, provided such board service does not prevent Employee from fulfilling the duties or responsibilities as set forth in or contemplated by this Agreement.

 

1.2             Location. Employee’s employment will be based at the Corporation’s corporate headquarters, located in New Prague, Minnesota as of the Effective Date. Employee will maintain a residential location in close proximity to the Corporation’s headquarters but will be permitted to work part-time from Dallas, Texas, provided such remote work does not interfere with Employee fulfilling the duties or responsibilities as set forth in or contemplated by this Agreement, as determined by the Board. Employee acknowledges and agrees that Employee’s position, duties and responsibilities will require regular travel, both in the U.S. and internationally.

 

 

 

 

 

2.                Term. Unless terminated at an earlier date in accordance with Section 5, the term of Employee’s employment with the Corporation under the terms and conditions of this Agreement will be for the period commencing on July 1, 2023 (the “Start Date”) and ending on the two (2) year anniversary of the Start Date (the “Initial Term”). On the two (2) year anniversary of the Start Date, and on each succeeding one-year anniversary of the Start Date (each an “Anniversary Date”), the Term shall be automatically extended until the next Anniversary Date (each a “Renewal Term”), subject to termination on an earlier date in accordance with Section 5 or unless either Party gives written notice of non-renewal to the other Party at least ninety (90) days prior to the Anniversary Date on which this Agreement would otherwise be automatically extended that the Party providing such notice elects not to extend the Term; provided, however, that if a Change in Control (as defined in Section 6.5) occurs during the Initial Term or during any Renewal Term then the Term will expire on the one-year anniversary of the date of the Change in Control. The Initial Term together with any Renewal Terms is the “Term.” If Employee remains employed by the Corporation after the Term ends for any reason, then such continued employment shall be according to the terms and conditions established by the Corporation from time to time (provided that any provisions of this Agreement and the Restrictive Covenants Agreement (as defined in Section 3) that by their terms survive the termination of the Term shall remain in full force and effect).

 

3.                Restrictive Covenants Agreement. Simultaneous with Employee’s execution of this Agreement, Employee is entering into a Non-Competition, Non-Solicitation, and Confidentiality Agreement in the form of Exhibit A attached hereto and made a part hereof (the “Restrictive Covenants Agreement”), and Employee acknowledges and agrees that the Corporation’s execution of this Agreement and agreement to employ Employee are conditioned upon Employee executing the Restrictive Covenants Agreement and agreeing to Employee’s commitments and obligations under the Restrictive Covenants Agreement. Nothing in this Agreement is intended to modify, amend, cancel or supersede the Restrictive Covenants Agreement in any manner.

 

4.                Compensation, Benefits and Business Expenses.

 

4.1             Base Salary. The Corporation will pay Employee an annualized base salary of $500,000.00 (the “Base Salary”), which Base Salary will be earned by Employee on a pro rata basis as Employee performs services and which shall be paid according to the Corporation’s normal payroll practices. Beginning on or about July 1, 2024, and on or about July 1 of each subsequent year during the Term, Employee shall be eligible for a merit-based increase of the Base Salary payable under this Section 4.1, with any adjustment to Employee’s Base Salary subject to approval by the Board.

 

4.2             Annual Incentive Compensation. For each of the Corporation’s fiscal years during the Term, Employee will be eligible to earn an annualized cash bonus as determined by the Board in its discretion and subject to the terms of any written document addressing such annual cash bonus as the Board may adopt in its sole discretion. For the Corporation’s fiscal year ending June 30, 2024, Employee’s target annualized cash bonus under this Section 4.2 will be fifty percent (50%) of Employee’s annualized Base Salary, subject to the terms and conditions identified in the applicable Management Bonus Plan. Future annual cash bonus opportunities will be determined by the Board in its discretion. Unless specified otherwise in a written annual cash bonus document applicable to Employee, if a bonus is earned in accordance with this Section 4.2, it will be paid to Employee by the Corporation regardless of whether Employee is employed by the Corporation on the payment date, with such payment date being no later than March 15 of the calendar year immediately following the calendar year in which Employee earns a bonus in accordance with this Section 4.2.

 

 2

 

 

4.3             Equity Incentive Compensation.

 

(a)    Performance-Based Restricted Stock Units. Subject to Employee being employed by the Corporation on July 1, 2023, on such date or as soon as practicable thereafter Employee shall be granted 175,000 Performance-Based Restricted Stock Units pursuant to the Corporation’s then-current Stock Incentive Plan or on substantially similar terms in the form of an inducement grant. The remaining terms of the grant will be governed by a restricted stock unit award agreement to be executed by the Corporation and Employee on or about the date of grant.

 

(b)    Non-Qualified Stock Options. Subject to Employee being employed by the Corporation on July 1, 2023, on such date or as soon as practicable thereafter Employee shall be granted a non-qualified stock option to purchase 175,0000 shares of the Corporation’s common stock pursuant to the Corporation’s then-current Stock Incentive Plan or on substantially similar terms in the form of an inducement grant. The option shall have an exercise price equal to the fair market value of the Corporation’s common stock on the date of the grant and shall have a 10-year term. The remaining terms of the option will be governed by a non-qualified stock option agreement to be executed by the Corporation and Employee on or about the date of grant.

 

4.4             Employee Benefits. While Employee is employed by the Corporation during the

 

Term, Employee shall remain entitled to participate in the retirement plans, equity compensation plans, health plans, and all other employee benefits made available by the Corporation, and as they may be changed from time to time. Employee acknowledges and agrees that Employee will be subject to all eligibility requirements and all other provisions of these benefits plans, and that the Corporation is under no obligation to Employee to establish and maintain any employee benefit plan in which Employee may participate. The terms and provisions of any employee benefit plan of the Corporation are matters within the exclusive province of the Board, subject to applicable law.

 

4.5             Discretionary Time Off. Employee will be subject to the Corporation’s Discretionary Time Off (“DTO”) practice, pursuant to which Employee may request time off for vacation, sick, or any other valid reason Employee needs, providing more flexibility of employee well-being, subject to Employee continuing to be able to satisfy Employee’s duties and responsibilities hereunder. DTO is not accrued, is not carried over year to year, and is not paid out upon termination of employment by the Corporation or Employee for any reason.

 

4.6             Business Expenses. While Employee is employed by the Corporation during the Term, the Corporation shall reimburse Employee for all reasonable and necessary out-of-pocket business, travel and entertainment expenses incurred by Employee in the performance of Employee’s duties and responsibilities hereunder, subject to the Corporation’s normal policies and procedures for expense verification and documentation.

 

5.                Termination of Employment.

 

5.1              Termination of Employment Events. Employee’s employment with the Corporation is at-will. Employee’s employment with the Corporation will terminate as follows:

 

(a)On the effective date following written notice from the Corporation of the termination of Employee’s employment as specified herein;

 

 3

 

 

(b)Upon Employee’s abandonment of Employee’s employment or the effective date of Employee’s resignation for Good Reason (as defined below) or any other reason (as specified in written notice from Employee);

 

(c)After thirty (30) days’ advance written notice to Employee by the Corporation of termination of Employee’s employment for Employee’s Disability (as defined below); or

 

(d)Immediately upon Employee’s death.

 

5.2           Termination Date. The date upon which Employee’s termination of employment with the Corporation is effective is the “Termination Date.” For purposes of Sections 6.1 and 6.2 only, with respect to the timing of the Pre-CIC Severance Payment or the Post-CIC Severance Payment (as applicable) and the Pre-CIC Benefits Continuation Payments or the Post-CIC Benefits Continuation Payments (as applicable), the Termination Date means the date on which a “separation from service” has occurred for purposes of Section 409A of the Internal Revenue Code, as amended, and the regulations and guidance thereunder (the “Code”).

 

6.             Payments Upon Termination of Employment.

 

6.1          Termination of Employment Without Cause or by Employee for Good Reason During the Term and Before the First Change in Control. If Employee’s employment with the Corporation is terminated during the Term by the Corporation for any reason other than for Cause (as defined in Section 6.4), or by Employee for Good Reason (as defined in Section 6.6), and the Termination Date occurs before the date of the first Change in Control (as defined in Section 6.5) to occur during the Term, then the Corporation shall, in addition to paying Employee’s Base Salary and other compensation and benefits earned through the Termination Date, plus all unreimbursed expenses in accordance with Section 4.6, and subject to Section 6.9,

 

(a)pay to Employee as severance pay (i) one (1) times Employee’s annualized Base Salary as of the Termination Date, payable in substantially equal installments over twelve (12) months after the Termination Date; provided that the first installment will be held until the Corporation’s first regular payroll date that is after the expiration of all rescission periods identified in the Release (as defined in Section 6.9), which will in no event be later than seventy-five (75) days after the Termination Date, plus (ii) an amount equal to Employee’s target annual bonus based on the Corporation’s performance for the fiscal year in which the Termination Date occurs, multiplied by a fraction, the numerator of which is the number of days Employee was employed by the Corporation during the fiscal year in which the Termination Date occurs and the denominator of which is 365, less all legally required and authorized deductions and withholdings, payable in a lump sum within seventy-five (75) days after the Termination Date (the “Pre-CIC Severance Payment”); and

 

(b)if Employee is eligible for and takes all steps necessary to continue Employee’s group health insurance coverage with the Corporation following the Termination Date (including completing and returning the forms necessary to elect COBRA coverage), pay for the portion of the premium costs for such coverage that the Corporation would pay if Employee remained employed by the Corporation, at the same level of coverage that was in effect as of the Termination Date, through the earliest of: (i) the twelve (12) month anniversary of the Termination Date, (ii) the date Employee becomes eligible for group health insurance coverage from any other employer, or (iii) the date Employee is no longer eligible to continue Employee’s group health insurance coverage with the Corporation under applicable law (“Pre-CIC Benefits Continuation Payment”).

 

 4

 

 

6.2            Termination of Employment Without Cause or by Employee for Good Reason During the Term and Within Twelve (12) Months after the First Change in Control. If Employee’s employment with the Corporation is terminated during the Term by the Corporation for any reason other than for Cause (as defined in Section 6.4), or by Employee for Good Reason (as defined in Section 6.6), and the Termination Date occurs on or within twelve (12) months after the date of the first Change in Control (as defined in Section 6.5) to occur during the Term, then the Corporation shall, in addition to paying Employee’s Base Salary and other compensation and benefits earned through the Termination Date, plus all unreimbursed expenses in accordance with Section 4.6, and subject to Section 6.9,

 

(c)pay to Employee as severance pay an amount equal to the sum of (i) one (1) times Employee’s annualized Base Salary as of the Termination Date, plus (ii) an amount equal to one hundred percent (100%) of Employee’s target annual bonus based on Employee’s individual performance for the fiscal year in which the Termination Date occurs, less all legally required and authorized deductions and withholdings, payable in a lump sum on the Corporation’s first regular payroll date that is after the expiration of all rescission periods identified in the Release (as defined in Section 6.9) but in no event later than seventy-five (75) days after the Termination Date (the “Post-CIC Severance Payment”); and

 

(d)if Employee is eligible for and takes all steps necessary to continue Employee’s group health insurance coverage with the Corporation following the Termination Date (including completing and returning the forms necessary to elect COBRA coverage), pay for the portion of the premium costs for such coverage that the Corporation would pay if Employee remained employed by the Corporation, at the same level of coverage that was in effect as of the Termination Date, through the earliest of: (i) the twelve (12) month anniversary of the Termination Date, (ii) the date Employee becomes eligible for group health insurance coverage from any other employer, or (iii) the date Employee is no longer eligible to continue Employee’s group health insurance coverage with the Corporation under applicable law (“Post-CIC Benefits Continuation Payments”).

 

6.3. Other Termination of Employment Events. If Employee’s employment with the Corporation is terminated by the Corporation or Employee for any reason upon or following the expiration of the Term, or if Employee’s employment with the Corporation is terminated during the Term by reason of:

 

(a)Employee’s abandonment of Employee’s employment or Employee’s resignation for any reason other than Good Reason;

 

(b)termination of Employee’s employment by the Corporation for Cause; or

 

(c)Employee’s death or Disability,

 

then the Corporation shall pay to Employee or Employee’s beneficiary or Employee’s estate, as the case may be, Employee’s Base Salary and other compensation and benefits earned through the Termination Date, plus all unreimbursed expenses in accordance with Section 4.6, and Employee shall not be eligible or entitled to receive any severance pay or benefits from the Corporation.

 

 5

 

 

6.4.         Cause Defined. “Cause” hereunder means:

 

(a)Employee’s material failure to perform Employee’s job duties competently as reasonably determined by the Board;

 

(b)gross misconduct by Employee which the Board determines is (or will be if continued) demonstrably and materially damaging to the Corporation;

 

(c)fraud, misappropriation, or embezzlement by Employee;

 

(d)conviction of a felony crime or a crime of moral turpitude;

 

(e)conduct in the course of employment that the Board determines is unethical; or

 

(f)the material breach of this Agreement or the Restrictive Covenants Agreement by Employee.

 

With respect to Section 6.4(a), Section 6.4(b) and Section 6.4(f), the Corporation shall first provide Employee with written notice and an opportunity to cure such breach, if curable, in the reasonable discretion of the Board, and identify with specificity the action needed to cure within thirty (30) days of Employee’s receipt of written notice from the Corporation. If the Corporation terminates Employee’s employment for Cause pursuant to this Section 6.4, then Employee shall not be eligible or entitled to receive any severance pay or benefits from the Corporation.

 

6.5.        Change in Control Defined. “Change in Control” hereunder means:

 

(a)A “change in ownership,” as described in Section 1.409A-3(i)(5)(v) of the Treasury Regulations;

 

(b)A “change in effective control,” as described in Section 1.409A-3(i)(5)(vi) of the Treasury Regulations; or

 

(c)A “change in ownership of a substantial portion of the assets,” as described in Section 1.409A-3(i)(5)(vii) of the Treasury Regulations.

 

6.6.         Good Reason Defined. “Good Reason” hereunder means the initial occurrence of any of the following events without Employee’s consent:

 

(a)a material diminution in the Employee’s responsibilities, authority or duties; or

 

(b)a material diminution in the Employee’s salary, other than pursuant to a reduction in the salary for all executive employees of the Corporation and its affiliates, applied on a pro rata basis to all salaried executives including Employee;

 

(c)receipt by Employee of a written non-renewal of this Agreement by the Corporation in accordance with Section 2; or

  

(d)the material breach of this Agreement by the Corporation.

 

 6

 

 

provided, however, that “Good Reason” shall not exist unless Employee has first provided written notice to the Corporation of the initial occurrence of one or more of the conditions under clauses (a) through (d) above within thirty (30) days of the condition’s occurrence, such condition is not fully remedied by the Corporation within thirty (30) days after the Corporation’s receipt of written notice from Employee, and the Termination Date as a result of such event occurs within ninety (90) days after the initial occurrence of such event.

 

6.7.        Disability Defined. “Disability” hereunder means the inability of Employee to perform on a full-time basis, with or without reasonable accommodation, the duties and responsibilities of Employee’s employment with the Corporation by reason of Employee’s illness or other physical or mental impairment or condition, if such inability continues for an uninterrupted period of at least one hundred (100) days or more during any 360-day period. A period of inability shall be “uninterrupted” unless and until Employee returns to full-time work for a continuous period of at least thirty (30) days. This Section 6.7 does not relieve the Corporation of any duty to reasonably accommodate a qualifying disability under the Americans with Disabilities Act, the Minnesota Human Rights Act, any legal duty under the Family Medical Leave Act, or any of its other duties pursuant to applicable law.

 

6.8.        The Corporation’s Sole Obligation. In the event of termination of Employee’s employment, the sole obligation of the Corporation shall be its obligation to make the payments called for by Section 6.1, Section 6.2 or Section 6.3, as the case may be, and the Corporation shall have no other obligation to Employee or to Employee’s beneficiary or Employee’s estate, except for any amounts due under the terms of any employee benefit plans or programs then maintained by the Corporation in which Employee participates.

 

6.9.        Conditions To Receive the Pre-CIC Severance Payment, Pre-CIC Benefits Continuation Payments, Post-CIC Severance Payment and Post-CIC Benefits Continuation Payments. Notwithstanding the foregoing provisions of this Section 6, the Corporation will not be obligated to make the Pre-CIC Severance Payment and Pre-CIC Benefits Continuation Payments under Section 6.1 or the Post-CIC Severance Payment and Post-CIC Benefits Continuation Payments under Section 6.2 (as applicable) to or on behalf of Employee unless (a) Employee signs a release of claims in favor of the Corporation in a form to be prescribed by the Corporation (the “Release”), (b) all applicable consideration periods and rescission periods provided by law with respect to the Release have expired without Employee rescinding the Release, and (c) Employee is in strict compliance with the terms of this Agreement and the Restrictive Covenants Agreement and any other written agreement between Employee and the Corporation.

 

7.           Section 409A and Taxes Generally.

 

7.1 Taxes. The Corporation shall be entitled to withhold on and report the making of such payments as may be required by law as determined in the reasonable discretion of the Corporation. Except for any tax amounts withheld by the Corporation from any compensation that Employee may receive in connection with Employee’s employment with the Corporation and any employer taxes required to be paid by the Corporation under applicable laws or regulations, Employee is solely responsible for payment of any and all taxes owed in connection with any compensation, benefits, reimbursement amounts or other payments Employee receives from the Corporation under this Agreement or otherwise in connection with Employee’s employment with the Corporation. The Corporation does not guarantee any particular tax consequence or result with respect to any payment made by the Corporation.

 

7.2 Section 409A. This Agreement is intended to provide for payments that satisfy, or are exempt from, the requirements of Section 409A, including Sections 409A(a)(2), (3) and (4) of the Code and current and future guidance and regulations interpreting such provisions, and should be interpreted accordingly. In furtherance of the foregoing, the provisions set forth below shall apply notwithstanding any other provision in this Agreement:

 

 7

 

 

(a)              all payments to be made to Employee hereunder, to the extent they constitute a deferral of compensation subject to the requirements of Section 409A (after taking into account all exclusions applicable to such payments under Section 409A), shall be made no later, and shall not be made any earlier, than at the time or times specified in this Agreement or in any applicable plan for such payments to be made, except as otherwise permitted or required under Section 409A;

 

(b)              the date of Employee’s “separation from service”, as defined in Section 409A (and as determined by applying the default presumptions in Treas. Reg. §1.409A-1(h)(1)(ii)), shall be treated as the date of Employee’s termination of employment for purposes of determining the time of payment of any amount that becomes payable to Employee related to Employee’s termination of employment under Section 6.1 or 6.2, and any reference to Employee’s “Termination Date” or “termination” of Employee’s employment in Section 6.1 or 6.2 shall mean the date of Employee’s “separation from service”, as defined in Section 409A (and as determined by applying the default presumptions in Treas. Reg. §1.409A-1(h)(1)(ii));

 

(c)              in the case of any amounts payable to Employee under this Agreement that may be treated as payable in the form of “a series of installment payments”, as defined in Treas. Reg. §1.409A-2(b)(2)(iii), Employee’s right to receive such payments shall be treated as a right to receive a series of separate payments for purposes of Treas. Reg. §1.409A-2(b)(2)(iii);

 

(d)              to the extent that the reimbursement of any expenses eligible for reimbursement or the provision of any in-kind benefits under any provision of this Agreement would be considered deferred compensation under Section 409A (after taking into account all exclusions applicable to such reimbursements and benefits under Section 409A): (i) reimbursement of any such expense shall be made by the Corporation as soon as practicable after such expense has been incurred, but in any event no later than December 31st of the year following the year in which Employee incurs such expense; (ii) the amount of such expenses eligible for reimbursement, or in-kind benefits to be provided, during any calendar year shall not affect the amount of such expenses eligible for reimbursement, or in-kind benefits to be provided, in any calendar year; and (iii) Employee’s right to receive such reimbursements or in-kind benefits shall not be subject to liquidation or exchange for another benefit;

 

(e)              to the extent any payment or delivery otherwise required to be made to Employee hereunder on account of Employee’s separation from service is properly treated as a deferral of compensation subject to Section 409A after taking into account all exclusions applicable to such payment and delivery under Section 409A, and if Employee is a “specified employee” under Section 409A at the time of Employee’s separation from service, then such payment and delivery shall not be made prior to the first business day after the earlier of (i) the expiration of six months from the date of Employee’s separation from service, or (ii) the date of Employee’s death (such first business day, the “Delayed Payment Date”), and on the Delayed Payment Date, there shall be paid or delivered to Employee or, if Employee has died, to Employee’s estate, in a single payment or delivery (as applicable) all entitlements so delayed, and in the case of cash payments, in a single cash lump sum, an amount equal to aggregate amount of all payments delayed pursuant to the preceding sentence. Except for any tax amounts withheld by the Corporation from the payments or other consideration hereunder and any employment taxes required to be paid by the Corporation, Employee shall be responsible for payment of any and all taxes owed in connection with the consideration provided for in this Agreement; and

 

 8

 

 

(f)               the Parties agree that this Agreement may be amended, as may be necessary to fully comply with, or to be exempt from, Section 409A and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either Party.

 

8.            Miscellaneous.

 

8.1       Integration. This Agreement and the Restrictive Covenants Agreement between Employee and the Corporation embody the entire agreement and understanding among the Parties relative to subject matter hereof and combined supersede all prior agreements and understandings relating to such subject matter, including but not limited to any earlier offers to Employee by the Corporation.

 

8.2       Applicable Law. All matters relating to the interpretation, construction, application, validity and enforcement of this Agreement are governed by the laws of the State of Minnesota without giving effect to any choice or conflict of law provision or rule, whether of the State of Minnesota or any other jurisdiction, that would cause the application of laws of any jurisdiction other than the State of Minnesota.

 

8.3       Choice of Jurisdiction. Employee and the Corporation consent to jurisdiction of the courts of the State of Minnesota and/or the federal district courts, District of Minnesota, for the purpose of resolving all issues of law, equity, or fact, arising out of or in connection with this Agreement or Employee’s employment with the Corporation or the termination of such employment. Any action involving claims for interpretation, breach or enforcement of this Agreement or related to Employee’s employment with the Corporation or the termination of such employment shall be brought in such courts. Each party consents to personal jurisdiction over such party in the state and/or federal courts of Minnesota and hereby waives any defense of lack of personal jurisdiction or inconvenient forum.

 

8.4       Employee’s Representations. Employee represents that Employee is not subject to any agreement or obligation that would prevent or limit Employee from entering into this Agreement or that would be breached upon performance of Employee’s duties under this Agreement, including but not limited to any duties owed to any former employers not to compete. If Employee possesses any information that Employee knows or should know is considered by any third party, such as a former employer of Employee’s, to be confidential, trade secret, or otherwise proprietary, Employee shall not disclose such information to the Corporation or use such information to benefit the Corporation in any way.

 

8.5       Counterparts. This Agreement may be executed in several counterparts and as so executed shall constitute one agreement binding on the Parties.

 

8.6       Assignment and Successors. The rights and obligations of the Corporation under this Agreement shall inure to the benefit of and will be binding upon the successors and assigns of the Corporation, provided any such successor or assignee assumes all of the Corporation’s obligations under this Agreement . Neither party may, without the written consent of the other party, assign or delegate any of its rights or obligations under this Agreement except that the Corporation may, without any further consent of Employee, assign or delegate any of its rights or obligations under this Agreement to any corporation or other business entity (a) with which the Corporation may merge or consolidate, (b) to which the Corporation may sell or transfer all or substantially all of its assets or capital stock or equity, or (c) any affiliate or subsidiary of the Corporation. After any such assignment or delegation by the Corporation, the Corporation will be discharged from all further liability hereunder and such assignee will thereafter be deemed to be the “Corporation” for purposes of all terms and conditions of this Agreement, including this Section 8.6. Employee may not assign this Agreement or any rights or obligations hereunder. Any purported or attempted assignment or transfer by Employee of this Agreement or any of Employee’s duties, responsibilities, or obligations hereunder is void.

 

 9

 

 

8.7         Modification. This Agreement shall not be modified or amended except by a written instrument signed by the Parties.

 

8.8         Severability. The invalidity or partial invalidity of any portion of this Agreement shall not invalidate the remainder thereof, and said remainder shall remain in fully force and effect.

 

8.9         Opportunity to Obtain Advice of Counsel. Employee acknowledges that Employee has been advised by the Corporation to obtain legal advice prior to executing this Agreement, and that Employee had sufficient opportunity to do so prior to signing this Agreement.

 

8.10       Indemnification. As to acts or omissions of Employee which are within the scope of Employee’s authority as an officer, director, or employee of the Corporation and/or any affiliate of the Corporation, the Corporation will indemnify Employee in accordance with and subject to the limitations contained in its Articles of Incorporation, Bylaws and Section 302A.521 of the Minnesota Business Corporations Act. If Employee is made or threatened to be made a party to any threatened, pending, or completed civil, criminal, administrative, arbitration, or investigative proceeding, including a proceeding by or in the right of the corporation, Employee is entitled, upon written request to the Corporation, to payment or reimbursement by the Corporation of reasonable expenses, including attorneys' fees and disbursements, incurred by Employee in advance of the final disposition of the proceeding, (a) upon receipt by the Corporation of a written affirmation by Employee of a good faith belief that the criteria for indemnification set forth in Section 302A.521, subdivision 2 of the Minnesota Business Corporations Act have been satisfied and a written undertaking by Employee to repay all amounts so paid or reimbursed by the Corporation, if it is ultimately determined that the criteria for indemnification have not been satisfied, and (b) after a determination that the facts then known to those making the determination would not preclude indemnification under the Corporation’s Articles of Incorporation and Bylaws and Section 302A.521 of the Minnesota Business Corporations Act, including but not limited to whether the alleged misconduct by Employee that is the subject of the proceeding is within the course and scope of Employee’s employment.

 

8.11       280G Limitations. In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Employee (a) constitute “parachute payments” within the meaning of Section 280G of the Code and (b) would be subject to the excise tax imposed by Code Section 4999, then such benefits shall be either be: (i) delivered in full, or (ii) delivered as to such lesser extent which would result in no portion of such severance benefits being subject to excise tax under Code Section 4999, whichever of the foregoing amounts, taking into account the applicable federal, state and local income and employment taxes and the excise tax imposed by Code Section 4999, results in the receipt by Employee, on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be subject to excise tax under Code Section 4999. Any determination required under this Section 8.11 will be made in writing by an accounting firm selected by the Corporation or such other person or entity to which the parties mutually agree (the “Accountants”), whose determination will be conclusive and binding upon Employee and the Corporation for all purposes. For purposes of making the calculations required by this Section 8.11, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Code Sections 280G and 4999. The Corporation and Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 8.11. The Corporation shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 8.11. Any reduction in payments and/or benefits required by this Section 8.11 shall occur in the following order: (A) cash payments shall be reduced first and in reverse chronological order such that the cash payment owed on the latest date following the occurrence of the event triggering such excise tax will be the first cash payment to be reduced; (B) accelerated vesting of stock awards, if any, shall be cancelled/reduced next and in the reverse order of the date of grant for such stock awards (i.e., the vesting of the most recently granted stock awards will be reduced first), with full value awards reversed before any stock option or stock appreciation rights are reduced; and (C) deferred compensation amounts subject to Section 409A shall be reduced last.

 

[Signature Page Follows]

 

 10

 

 

THIS EMPLOYMENT AGREEMENT was voluntarily and knowingly executed by the Parties effective as of the Effective Date first identified above.

 

Corporation:
   
 ELECTROMED, INC.
   
Date May 22, 2023/s/ Lee A. Jones
 By:Lee A. Jones
 Its:Chair of the Board
   
 Employee:
   
Date  May 19, 2023/s/ James Cuniff
 JAMES CUNIFF

 

 

 

Exhibit 10.2

 

May 22, 2023

 

James Cunniff (by email: [Redacted])

 

Dear Jim,

 

In connection with your anticipated employment with Electromed, Inc. (the “Corporation”) under the terms of the Employment Agreement between you and the Corporation effective as of July 1, 2023 (the “Employment Agreement”), we are offering relocation assistance of up to $30,000 (the “Relocation Assistance”), according to the terms and conditions set forth in this letter (“Relocation Letter”). Capitalized terms used but not defined in this Relocation Letter have the meanings set forth in the Employment Agreement.

 

Your eligibility for the Relocation Assistance is conditioned on your becoming employed by the Corporation and your relocation to the New Prague, Minnesota area. The Relocation Assistance may only be used for qualifying expenses and is subject to your submission of receipts confirming you incurred and paid qualifying expenses. Qualifying expenses include: (i) payment of rental costs for reasonably acceptable temporary housing in the New Prague, Minnesota area for you and your immediate family for up to six (6) months while you search for a permanent residence, plus (ii) the actual travel costs for up to two round trips by you and your spouse from Dallas, Texas to Minneapolis, Minnesota, plus (iii) the reasonable costs of moving or purchasing household goods and personal effects to your residence in the New Prague, Minnesota area; provided, however, that the total combined reimbursement amounts for qualifying expenses may not exceed $30,000.

 

If you do not commence employment with the Corporation, or if you resign employment with the Corporation without Good Reason or your employment with the Corporation is terminated for Cause within twelve (12) months of the Effective Date of the Employment Agreement, then you agree to promptly reimburse the Corporation for all Relocation Assistance expenditures made by the Corporation pursuant to this Relocation Letter. For example, if you resign without Good Reason or your employment is terminated for Cause six months after the Effective Date, then you must promptly reimburse the Corporation for all Relocation Assistance amounts. 

 

You will be responsible for the full amount of any tax or other withholding that may be due as a consequence of receiving the Relocation Assistance. Additionally, payments and benefits under this Relocation Letter are intended to comply with Internal Revenue Code Section 409A and applicable guidance issued thereunder (“Section 409A”) or comply with an exemption from the application of Section 409A and, accordingly, all provisions of this Relocation Letter shall be construed and administered in accordance with Section 409A. Notwithstanding any of the provisions of this Relocation Letter, the Corporation shall not be liable to you for any excise taxes or interest if any payment or benefit which is to be provided pursuant to this Relocation Letter and which is considered deferred compensation subject to Section 409A otherwise fails to comply with, or be exempt from, the requirements of Section 409A.

 

This Relocation Letter does not modify the at-will employment relationship between you and the Corporation, as described in the Employment Agreement.

 

 

 

 

All matters relating to the interpretation and enforcement of this Relocation Letter will be governed by the laws of the State of Minnesota. This Relocation Letter may not be assigned by you. The Corporation may assign this Relocation Letter to any successor, parent or affiliate of the Corporation without further consent by you.

 

This Relocation Letter contains the entire agreement and understanding between the Corporation and you with respect to your eligibility for any relocation payments or reimbursement of relocation expenses. This Relocation Letter may not be modified or amended except in a written amendment signed by you and an authorized representative of the Corporation.

 

Sincerely,

 

ELECTROMED, INC.

 

/s/ Lee A. Jones

 

Lee A. Jones

Chair of the Board

 

I accept and agree to the terms and conditions of this Relocation Letter as set forth above.

 

 

  /s/ James Cunniff  
  James Cunniff  

 

 

 

Exhibit 99.1

 

Electromed Names Jim Cunniff as President and Chief Executive Officer

 

Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed

 

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed’s Board of Directors.

 

“We are pleased to announce the appointment of Jim Cunniff as president and CEO,” said Lee Jones, Chair of the Board. “Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams.

 

“As Kathleen Skarvan, our current CEO retires, I want to thank her for exceptional leadership over 10 years at Electromed. The company is in a strong position as a result, and we are pleased that she has agreed to continue to serve as Chair of the Board.”

 

Mr. Cunniff brings over 30 years of executive leadership in the MedTech and broader healthcare industry with demonstrated success in general management, sales and marketing, finance, manufacturing, distribution, mergers, and acquisitions. Mr. Cunniff will be joining Electromed from his role as President, Chief Executive Officer, and Board Director of Provista, a Vizient company, where he consistently grew revenue, executed two acquisitions, and shaped the strategic plan for the company. Previously, Cunniff was the President, Chief Executive Officer, and Board Director for Leiters, the Senior Vice President of Americas for Kinetics Concepts, and the President of Emerging Markets for Stryker Corporation.

 

“I am thrilled that Jim Cunniff will be my successor as President and Chief Executive Officer of Electromed and look forward to working with him as I transition to the Chair role,” said Kathleen Skarvan, longtime Chief Executive Officer of Electromed. “I am incredibly proud of what the Electromed team has accomplished under my leadership over the past decade, and I am confident that Jim is the ideal candidate to lead Electromed into its next phase of growth.”

 

“I am delighted to be joining this dynamic company, and to collaborate closely with Kathleen, the Board and the management team during the transition,” said Jim Cunniff, incoming President and Chief Executive Officer. “I look forward to continuing to deliver against strategic initiatives, grow commercial adoption and deliver strong shareholder results.”

 

About Electromed, Inc.

 

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

 

Cautionary Statements

 

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “assume,” “believe,” “continue,” “expect,” “may,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of

 

 

 

 

identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, component or raw material shortages, changes to lead times or significant price increases, changes to Medicare, Medicaid, or private insurance reimbursement policies; the duration, extent and severity of the COVID-19 pandemic, including its effects on our business, supply chain, operations and employees as well as its impact on our customers and distribution channels and on economies and markets more generally; the competitive nature of our market; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

 

Contacts

 

Brad Nagel, Chief Financial Officer
(952) 758-9299
investorrelations@electromed.com

Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com

 

Source: Electromed, Inc.